Xadago
Named-patient access overview. Xadago is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Xadago (safinamide) is a selective, reversible monoamine oxidase B (MAO-B) inhibitor developed by Newron Pharmaceuticals and marketed in the United States by US WorldMeds. The US Food and Drug Administration approved Xadago in March 2017 as adjunctive treatment to levodopa/carbidopa in patients with Parkinson disease experiencing OFF episodes. It is dosed orally once daily, starting at 50 mg and increasing to 100 mg after two weeks based on individual response and tolerability.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Xadago
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Xadago is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Xadago in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Xadago
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.